259 related articles for article (PubMed ID: 19521678)
1. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.
Walter H; Kammerer H; Frasch K; Spitzer M; Abler B
Psychopharmacology (Berl); 2009 Sep; 206(1):121-32. PubMed ID: 19521678
[TBL] [Abstract][Full Text] [Related]
2. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients.
Nielsen MØ; Rostrup E; Wulff S; Bak N; Lublin H; Kapur S; Glenthøj B
Biol Psychiatry; 2012 May; 71(10):898-905. PubMed ID: 22418013
[TBL] [Abstract][Full Text] [Related]
3. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study.
Abler B; Erk S; Walter H
Psychopharmacology (Berl); 2007 Apr; 191(3):823-33. PubMed ID: 17265148
[TBL] [Abstract][Full Text] [Related]
4. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.
Juckel G; Schlagenhauf F; Koslowski M; Filonov D; Wüstenberg T; Villringer A; Knutson B; Kienast T; Gallinat J; Wrase J; Heinz A
Psychopharmacology (Berl); 2006 Aug; 187(2):222-8. PubMed ID: 16721614
[TBL] [Abstract][Full Text] [Related]
5. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.
Schlagenhauf F; Juckel G; Koslowski M; Kahnt T; Knutson B; Dembler T; Kienast T; Gallinat J; Wrase J; Heinz A
Psychopharmacology (Berl); 2008 Mar; 196(4):673-84. PubMed ID: 18097655
[TBL] [Abstract][Full Text] [Related]
6. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment.
Snitz BE; MacDonald A; Cohen JD; Cho RY; Becker T; Carter CS
Am J Psychiatry; 2005 Dec; 162(12):2322-9. PubMed ID: 16330597
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the reward system by antipsychotic treatment.
Juckel G
Dialogues Clin Neurosci; 2016 Mar; 18(1):109-14. PubMed ID: 27069385
[TBL] [Abstract][Full Text] [Related]
8. Hyperresponsivity and impaired prefrontal control of the mesolimbic reward system in schizophrenia.
Richter A; Petrovic A; Diekhof EK; Trost S; Wolter S; Gruber O
J Psychiatr Res; 2015 Dec; 71():8-15. PubMed ID: 26522867
[TBL] [Abstract][Full Text] [Related]
9. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.
Bertolino A; Caforio G; Blasi G; De Candia M; Latorre V; Petruzzella V; Altamura M; Nappi G; Papa S; Callicott JH; Mattay VS; Bellomo A; Scarabino T; Weinberger DR; Nardini M
Am J Psychiatry; 2004 Oct; 161(10):1798-805. PubMed ID: 15465976
[TBL] [Abstract][Full Text] [Related]
10. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients.
Kirsch P; Ronshausen S; Mier D; Gallhofer B
Pharmacopsychiatry; 2007 Sep; 40(5):196-8. PubMed ID: 17874350
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.
da Silva Alves F; Bakker G; Schmitz N; Abeling N; Hasler G; van der Meer J; Nederveen A; de Haan L; Linszen D; van Amelsvoort T
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1577-86. PubMed ID: 23978392
[TBL] [Abstract][Full Text] [Related]
12. [Cognition, schizophrenia and the effect of antipsychotics].
Stip E
Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
[TBL] [Abstract][Full Text] [Related]
13. Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
Bédard AM; Maheux J; Lévesque D; Samaha AN
Schizophr Bull; 2013 May; 39(3):692-702. PubMed ID: 22927669
[TBL] [Abstract][Full Text] [Related]
14. Brain responses to different types of salience in antipsychotic naïve first episode psychosis: An fMRI study.
Knolle F; Ermakova AO; Justicia A; Fletcher PC; Bunzeck N; Düzel E; Murray GK
Transl Psychiatry; 2018 Sep; 8(1):196. PubMed ID: 30242202
[TBL] [Abstract][Full Text] [Related]
15. Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.
Blasi G; Popolizio T; Taurisano P; Caforio G; Romano R; Di Giorgio A; Sambataro F; Rubino V; Latorre V; Lo Bianco L; Fazio L; Nardini M; Weinberger DR; Bertolino A
Psychiatry Res; 2009 Jul; 173(1):31-8. PubMed ID: 19428222
[TBL] [Abstract][Full Text] [Related]
16. Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia.
Dowd EC; Barch DM
PLoS One; 2012; 7(5):e35622. PubMed ID: 22574121
[TBL] [Abstract][Full Text] [Related]
17. Altered effect of dopamine transporter 3'UTR VNTR genotype on prefrontal and striatal function in schizophrenia.
Prata DP; Mechelli A; Picchioni MM; Fu CH; Toulopoulou T; Bramon E; Walshe M; Murray RM; Collier DA; McGuire P
Arch Gen Psychiatry; 2009 Nov; 66(11):1162-72. PubMed ID: 19884604
[TBL] [Abstract][Full Text] [Related]
18. Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.
Kumari V; Ettinger U; Lee SE; Deuschl C; Anilkumar AP; Schmechtig A; Corr PJ; Ffytche DH; Williams SC
Psychopharmacology (Berl); 2015 Sep; 232(17):3135-47. PubMed ID: 25980483
[TBL] [Abstract][Full Text] [Related]
19. Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.
Müller JL; Deuticke C; Putzhammer A; Röder CH; Hajak G; Winkler J
Psychiatry Clin Neurosci; 2003 Dec; 57(6):562-8. PubMed ID: 14629703
[TBL] [Abstract][Full Text] [Related]
20. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
Lang DJ; Kopala LC; Vandorpe RA; Rui Q; Smith GN; Goghari VM; Lapointe JS; Honer WG
Am J Psychiatry; 2004 Oct; 161(10):1829-36. PubMed ID: 15465980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
